RxDoctor Payments Data

Nikki Gilbert

Family · Tallahassee, FLNPI 1568140135

Payments from drug & device makers

$1,199in general payments, 2019–2025

Across 42 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
  • Philips North America LLC$194
  • AstraZeneca$181
  • Pfizer$178
  • Boston Scientific$172
  • Lilly USA, LLC$72
  • plus $197 from 6 others

What the payments were for

  • Food & beverage$1,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,199 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$60,674
Medicare patients
341
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban383$350,298
EntrestoSacubitril/Valsartan79$75,463
FarxigaDapagliflozin Propanediol65$56,003
XareltoRivaroxaban83$53,411
JardianceEmpagliflozin18$11,085
Dofetilide53$7,052
Metoprolol Succinate315$5,313
Flecainide Acetate32$1,802
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$1,406
Potassium Chloride82$766
SotalolSotalol Hcl41$754
Digoxin41$559
Metoprolol Tartrate60$391
Amiodarone Hcl19$288
Furosemide82$276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$350,298383 claims
NovartisEntresto$14$75,46379 claims
AstraZenecaFarxiga$181$56,00365 claims
Johnson & JohnsonXarelto$58$53,41183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →